Related Experiment Video

Updated: Jun 17, 2026

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Effects of beta-blockers on glucose and lipid metabolism

Vivian A Fonseca1

  • 1Tulane University School of Medicine, New Orleans, LA, USA. vfonseca@tulane.edu

Current Medical Research and Opinion
|January 14, 2010
PubMed

Insights

Vasodilating beta-blockers improve glucose and lipid metabolism in hypertensive patients, unlike nonvasodilating types. This may reduce coronary artery disease risk in high-risk individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Syndrome

Background:

  • Sympathetic nervous system (SNS) activation is linked to hypertension.
  • Beta-blockers lower blood pressure but raise concerns about metabolic side effects.
  • Physicians hesitate to prescribe beta-blockers due to potential impacts on glycemic control and lipid profiles.

Purpose of the Study:

  • Review hypertension pathophysiology and metabolic effects of beta-blockers.
  • Compare glucose and lipid metabolism effects of vasodilating vs. nonvasodilating beta-blockers.
  • Assess impact on cardiovascular morbidity and mortality.

Main Methods:

  • Literature search of PubMed (1980-2008) for randomized, controlled trials (≥100 patients).
  • Focused on effects of specific nonvasodilating (atenolol, metoprolol, propranolol) and vasodilating (carvedilol, labetalol, nebivolol) beta-blockers.
  • Analyzed impact on glucose and lipid metabolism parameters in hypertensive patients.

Main Results:

  • Beta-blockers exhibit varied effects on glucose and lipid metabolism.
  • Nonvasodilating beta-blockers may worsen glycemic and lipid control.
  • Vasodilating beta-blockers demonstrate more favorable metabolic profiles compared to nonvasodilating agents.

Conclusions:

  • Vasodilating beta-blockers show improved glucose and lipid metabolism.
  • These metabolic improvements may decrease coronary artery disease risk.
  • Beneficial for high-risk hypertensive patients.
Abstract

More Related Videos

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets08:50

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets

Published on: July 3, 2018

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...